Rubio-Herrera, M.A.; Mera-Carreiro, S.; Sánchez-Pernaute, A.; Ramos-Levi, A.M.
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery. Biomedicines 2023, 11, 2785.
https://doi.org/10.3390/biomedicines11102785
AMA Style
Rubio-Herrera MA, Mera-Carreiro S, Sánchez-Pernaute A, Ramos-Levi AM.
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery. Biomedicines. 2023; 11(10):2785.
https://doi.org/10.3390/biomedicines11102785
Chicago/Turabian Style
Rubio-Herrera, Miguel A., Sara Mera-Carreiro, Andrés Sánchez-Pernaute, and Ana M. Ramos-Levi.
2023. "Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery" Biomedicines 11, no. 10: 2785.
https://doi.org/10.3390/biomedicines11102785
APA Style
Rubio-Herrera, M. A., Mera-Carreiro, S., Sánchez-Pernaute, A., & Ramos-Levi, A. M.
(2023). Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery. Biomedicines, 11(10), 2785.
https://doi.org/10.3390/biomedicines11102785